GlassScriptPhysician profile
Chris Garcia
NPI 1588625560
$2,388.85
in general payments reported to CMS, 2019-2025
24 companies · $240 in 2025
The $240 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $147 · 2021: $13.00 · 2022: $211 · 2023: $356 · 2024: $1,286 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,001 · Food and Beverage: $880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,001.35 |
| Food and Beverage | $880.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,001.35 | 2024 | |
| Gilead Sciences, INC. | $364.29 | 2022-2025 | Epclusa |
| E.R. Squibb & Sons, L.L.C. | $154.76 | 2019-2024 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $124.99 | 2023 | |
| Dexcom, INC. | $124.99 | 2023 | Dexcom G7 Gss (161) |
| Daiichi Sankyo INC. | $124.99 | 2024 | Enhertu |
| Bioventus LLC | $80.06 | 2020 | |
| Alcon Vision LLC | $46.22 | 2022 | |
| Merck Sharp & Dohme LLC | $45.99 | 2020-2021 | |
| Procept Biorobotics Corporation | $40.50 | 2025 | |
| Abbvie INC. | $36.85 | 2022 | |
| Abbott Laboratories | $35.02 | 2022-2023 | Freestyle Libre 3 |
| Tolmar Pharmaceuticals, INC. | $30.38 | 2019 | |
| Antares Pharma, INC. | $20.93 | 2020 | |
| Organon LLC | $20.92 | 2025 | Nexplanon |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $19.82 | 2024 | Aptima, Thinprep 2000 Processor |
| Lilly USA, LLC | $18.21 | 2024 | Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.85 | 2019 | |
| Endo Pharmaceuticals INC. | $14.92 | 2019 | |
| Novo Nordisk INC | $14.50 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.71 | 2023 | Farxiga |
| Glaxosmithkline, LLC. | $12.96 | 2019 | |
| Shire North American Group INC | $12.90 | 2019 | |
| Acerus Pharmaceuticals Corporation | $12.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.